摘要
表皮生长因子受体抑制剂在结直肠癌治疗中的应用效果显著,近年来一系列的基础、临床研究表明,抗表皮长因子受体的单克隆抗体(C-225)联合化学治疗其疗效和生存均优于单纯化学治疗。表皮生长因子酪氨酸激酶受体抑制剂的临床研究结果到目前为止还不理想,但就目前的研究结果对其疗效进行评价还为时过早。目前有一些正在进行Ⅰ期临床研究的新型表皮生长因子受体的单克隆抗体和酪氨酸激酶受体抑制剂,有可能给结直肠癌的治疗带来新的希望。
Anti -epidermal growth factor receptor for colorectal cancer therapy is positive result, in recent years, a series of preclinical and clinical trials means that anti - epidermal growth factor receptor monocolonal antibody （cetuximab） combination with chemotherapy is better than chemotherapy alone Clinical trials of anti - epidermal growth factor receptor tyrosine kinase are still not clear, but it is not the time to appraise the treatment. Today, some new anti -epidermal growth factor receptor monocolonal antibody and anti -epidermal growth factor receptor tyrosine kinase during the phase I trials will bring some new changes to colorectal cancer therapy.
出处
《癌症进展》
2006年第6期517-522,共6页
Oncology Progress
